# SPRO PDUFA Calendar: FDA Decision Dates & Catalyst Timeline

Canonical URL: https://biopharmsignal.com/pdufa-calendar/SPRO
Company: Spero Therapeutics

BioPharmSignal tracks active PDUFA and FDA decision milestones associated with SPRO.

## SPRO PDUFA Milestones

- 2026-06-18 — PDUFA — FDA approved UTEBZI. FDA approved the first oral carbapenem in the United States for specified adults with complicated urinary tract infections, including py...
  Company: Spero Therapeutics
  Source: https://www.globenewswire.com/news-release/2026/06/17/3313706/0/en/Utebzi-tebipenem-pivoxil-approved-in-the-US-for-adults-with-complicated-urinary-tract-infections-cUTIs.html
  Event detail: https://biopharmsignal.com/pdufa-calendar/SPRO/tebipenem-hbr-complicated-urinary-tract-infections-review-2.md
  Month page: https://biopharmsignal.com/pdufa-calendar/2026/june (June 2026)

## Related Pages

- Company page: https://biopharmsignal.com/company/SPRO
- Interactive PDUFA Calendar: https://biopharmsignal.com/pdufa-calendar

## FAQ

### What does the SPRO PDUFA calendar show?

It shows active PDUFA and FDA decision milestones associated with SPRO, including decision dates, application stage, and summary details when available.
### Where can I find more context for SPRO?

Use the BioPharmSignal company page for SPRO to read related news, stock data, sector context, and company-specific updates.
### Are these dates investment advice?

No. PDUFA dates are research inputs, not investment recommendations. Always review primary sources and understand the clinical and regulatory context.